IL12A _ NKSF1 Antibody (Antigen Affinity Purified)
- Known as:
- IL12A _ NKSF1 Antibody (Antigen Affinity Purified)
- Catalog number:
- 10021-RP02
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- IL12A _ NKSF1 Antibody (Antigen Affinity Purified)
Related genes to: IL12A _ NKSF1 Antibody (Antigen Affinity Purified)
- Gene:
- IL12A NIH gene
- Name:
- interleukin 12A
- Previous symbol:
- NKSF1
- Synonyms:
- CLMF, IL-12A, p35, NFSK
- Chromosome:
- 3q25.33
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-08
- Date modifiied:
- 2014-11-18
Related products to: IL12A _ NKSF1 Antibody (Antigen Affinity Purified)
Related articles to: IL12A _ NKSF1 Antibody (Antigen Affinity Purified)
- We recently reported an immune profile that stratifies patients with axial spondyloarthritis based on clinical response to secukinumab. We now undertake an exploratory study on the secukinumab nonresponder patients to determine if immunologic changes occur during their initial secukinumab treatment that could determine their next biologic response. - Source: PubMed
Pacheco AddisonRemalante-Rayco PatriciaHaroon NigilPoddubnyy DenisInman Robert D - Upper respiratory tract infections (URTIs) are common viral illnesses whose burden increases with age-related declines in innate immunity. Maitake mushrooms () have immunomodulatory properties, but evidence in healthy humans, particularly regarding age-related innate immune responses, remains limited. In this randomized, double-blind, placebo-controlled trial, healthy young adults (18-20 years) and middle-aged/older adults (40-85 years) consumed bread containing one of two maitake strains (Y10M or C5304) or a placebo daily for 11 weeks (young adults) or 18 weeks (middle-aged/older adults). While the overall incidence of URTI episodes did not differ between groups, symptom-specific analyses suggested strain-dependent differences. Y10M supplementation was associated with fewer cumulative days of fever and runny nose in both age groups and with sore throat in young adults, whereas C5304 showed limited effects. Notably, Y10M was associated with changes in innate immune parameters in middle-aged/older adults, including increased plasmacytoid dendritic cell frequency, activation of conventional dendritic cells, and upregulation of type I interferon-related gene expression and following stimulation. These findings suggest that dietary maitake supplementation, particularly with the Y10M strain, may reduce the cumulative burden of selected URTI-related symptoms and modulate antiviral innate immune responses in healthy adults, with effects that may differ by strain and age cohort. - Source: PubMed
Publication date: 2026/08/21
Masuda YukiNakayama YoshiakiShimizu RyoheiJogi Eri MKato Masaharu CYamasaki KenjiAoki RyutaroHashimoto MichioOhno MihoOhata ShuzoKato SetsushiKonishi Morichika - Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by over 200 risk variants identified through genome-wide association studies. While the majority of these are non-coding variants with unresolved functions, elucidating their mechanisms is critical for prioritizing therapeutic targets with increased clinical success. Several SLE risk loci span genes involved in the IL-12 signaling pathway. However, for most of them the causal variants, their definitive target genes, and their cellular consequences remain unestablished. Concurrently the expansion of double-negative 2 (DN2) B cells is a hallmark of SLE, but whether IL-12 and/or genetic risk functionally drive DN2 cells is unclear. In this study, we integrated candidate risk variants at the 3q25.33 risk locus with regulatory maps of a B cell line, identifying risk variant rs485499 located within a putative enhancer 39kb downstream of , and overlapping an open chromatin region in primary B cells stimulated with a DN2-skewing cocktail. Using CRISPR-based tools in a B cell line, we validated this region as an enhancer, rs485499 as a likely causal variant and established as its definitive target gene. Individuals homozygous for the rs485499 risk allele exhibited elevated production in naïve B cells and presented with an expanded DN2 population in peripheral blood, compared to non-risk allele carriers. Mechanistically, we found the transcription factor IRF4 preferentially binds the rs485499 risk allele, driving upregulation. recombinant IL-12A promoted DN2 differentiation an effect that is abrogated by IL-12 inhibition with ustekinumab, establishing a causal IL-12-driven DN2 B cell expansion axis. Finally, we reveal that DN2 B cells inherently possess a previously unrecognized cytotoxic function that is potentiated by the IL-12 signaling axis. This cytotoxic profile is further supported by SLE patient data, identifying it as a bona fide effector state of DN2 B cells. Collectively, these findings identify rs485499 as a likely causal variant within this locus and establish a functional link between genetic risk and DN2 B cell expansion, validating this subset as a key pathogenic driver armed with a newly identified cytotoxic program. Furthermore, we identify the IL-12-IFNy-DN2 axis as a promising therapeutic target, providing a mechanistic rationale for future subset-specific interventions in SLE. - Source: PubMed
Publication date: 2026/07/29
Colantuoni MariasilviaXiao QianAziz Nada AbdelAguiar Vitor R CDjeddi SarahLiao YifeiFernandez-Salinas DanielaKim TaehyeungLewandowski Laura BGu JinghuaBalaji UthraWright TraceyChang Joyce CPascual VirginiaNigrovic Peter AGewurz Benjamin EGutierrez-Arcelus Maria - MECOM rearrangements (MECOM-r) are high-risk events in myeloid neoplasms often cryptic or incompletely characterized by conventional karyotype analysis. We used optical genome mapping (OGM) to define the frequency and spectrum of MECOM-r in an unselected, consecutively collected cohort of individuals with high-grade myeloid neoplasms (HGMNs) and compared these findings with standard cytogenetic approaches. - Source: PubMed
Salcedo-Porras NicolasAlBulushi FatmaParlow Julia N CMcGinnis EricSpence Tara - Yeast culture (YC) is widely applied as a functional feed additive, yet the mechanisms by which it regulates hepatic health, metabolism, and immune capacity in teleosts remain unclear. Here, juvenile were fed diets supplemented with 2.0% (YC2.0) or 8.0% YC (YC8.0) for 60 days, followed by hepatic histophysiological assessment, liver transcriptomic/metabolomic profiling, and an in vitro hepatocyte challenge with nervous necrosis virus (NNV). YC2.0 pincreased lipid droplet accumulation, improved antioxidant status, and lower aspartate aminotransferase(AST)/alanine aminotransferase (ALT)/alkaline phosphatase (ALP) and MDA in the liver than the control (Con) and YC8.0 groups. RNA-seq identified 915 hepatic differentially expressed genes (DEGs): YC2.0-specific genes were enriched in steroid hormone biosynthesis, bile secretion, and rhythmic regulation, whereas YC8.0-upregulated clusters were enriched in NOD-like receptor and JAK-STAT signaling, hematopoietic cell lineage, and apoptosis, with elevated immune- and apoptosis-related markers (, , , , and ). Metabolomics identified 680 differential metabolites across the three groups, showing that YC2.0 predominantly enhanced purine/nucleotide and glycerophospholipid metabolism, while YC8.0 shifted toward amino acid-centered pathways (arginine biosynthesis, histidine metabolism, and FoxO signaling). Multiomics integration revealed positive correlations of L-aspartic acid (L-Asp) and glutamic acid (Glu) with inflammatory DEGs, and of glycerophosphoethanolamine (Geptn) with apoptosis-related DEGs. In vitro, YC pretreatment alleviated NNV-induced cytopathic effects (CPEs) in hepatocytes, suppressed viral mRNA accumulation, and reduced the mRNA levels of inflammatory cytokines (β, , , , , and ) and immune pathway related DEGs. Collectively, these results characterize dose-dependent effects of YC on hepatic physiology and immune regulation, supporting its application as a functional aquafeed supplement. - Source: PubMed
Publication date: 2026/07/17
Yin ChenlinWang BoTang HaizhanZhang TongyaoZhai ZhongyiLi JiahangJin ChaofanBao ZhenminHu Jingjie